Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 843 of 1,261
  1. US 8580923

    Self-assembling peptide amphiphiles and related methods for growth factor delivery

    Northwestern University · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  2. US 8580944

    Suppressors of CpG oligonucleotides and methods of use

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  3. US 8580748

    Peptides for the treatment of hearing

    Compass Therapeutics LLC · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  4. US 8580735

    Local complement inhibition for treatment of complement-mediated disorders

    Apellis Pharmaceuticals, Inc. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  5. US 8580263

    Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof

    The Regents of the University of California · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  6. US 8580773

    Small-molecule inhibitors of the androgen receptor

    The Regents of the University of California · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  7. US 8580738

    Methods for treatment of reperfusion injury and other cardiac conditions

    The Board of Regents of the University of Texas System · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  8. US 8580845

    Functionalized expanded porphyrins

    The Board of Regents of the University of Texas System · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  9. US 8580802

    Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases

    Vertex Pharmaceuticals Incorporated · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  10. US 8580811

    Androgen receptor modulator methods

    Ligand Pharmaceuticals Incorporated · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  11. US 8580822

    Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors

    REVIVA PHARMACEUTICALS, INC. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  12. US 8580927

    Engineered antibody constant domain molecules

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  13. US 8580844

    Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities

    Georgia Regents Research Institute, Inc. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  14. US 8580852

    2-oxamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudopeptides

    The Regents of the University of California · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  15. US 8580768

    Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  16. US 8580936

    Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

    Five Prime Therapeutics, Inc. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  17. US 8580819

    Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  18. US 8580252

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    HALOZYME, INC. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  19. US 8580249

    Cell therapy for the treatment of lysosomal storage disorders

    Regents of the University of Minnesota · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  20. US 8580921

    Protein nanorings

    Regents of the University of Minnesota · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  21. US 8580231

    Compositions and methods comprising magnetic resonance contrast agents

    Northwestern University · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  22. US 8580290

    Heparosan-based biomaterials and coatings and methods of production and use thereof

    The Board of Regents of the University of Oklahoma · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  23. US 8580293

    Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof

    TEVA WOMEN'S HEALTH, INC. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  24. US 8580245

    Compositions and methods for treating and preventing cardiomyopathy and heart disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.